Relapsed/Refractory Malignant Lymphomas
Conditions
Keywords
Hodgkin Lymphoma, Non-Hodgkin lymphoma, autologous hematopoietic stem-cell transplantation, conditioning regimen
Brief summary
Nowadays there is no randomized trials for comparison the effectiveness and tolerability of different conditioning regimens. Bendamustine is a unique chemotherapeutic agent that combines alkylating action of nitrogen mustard and the activity of purine antimetabolite. Bendamustine has shown its effectiveness for the treatment of patients with chronic lymphoproliferative diseases such as chronic lymphocytic leukemia and several indolent lymphomas. The literature also presents evidence of the effectiveness bendamustine in patients with Hodgkin's lymphoma who received multiple lines of prior chemotherapy, including high dose chemotherapy and transplantation of peripheral hematopoietic stem cells. There are also data of using bendamustine as a part of conditioning regimen. In this context, it was planned a study for evaluation the safety and effectiveness of the BeEAC (bendamustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen prior to autologous transplantation of peripheral hematopoietic stem cells for the treatment of relapsed/refractory malignant lymphomas.
Interventions
DRUGBendamustine
BeEAC conditioning regimen: bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)
Sponsors
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be willing and able to provide written informed consent for the trial 2. Be ≥ 18 years of age on day of signing informed consent 3. Eastern Cooperative Oncology Group (ECOG) \< 2. 4. Relapsed/refractory malignant lymphoma patients with indications to autologous hematopoietic stem-cell transplantation
Exclusion criteria
1. Participation in another clinical trials 2. Clinically relevant heart disease: * Myocardial infarction during previous 6 months * Unstable angina during previous 3 months * Congestive heart failure (III-IV NYHA) * Clinically relevant ventricular arrhythmias * corrected QT interval (QTc) \> 460 мс on ECG (calculated using Frederics formula) * Left ventricular ejection fraction ≤ 45% on Echocardiogram * Atrial Hypotension (systolic pressure \< 86 mmHg) or bradycardia (\< 50 per minute, exclusion - drug-induced bradycardia) * Uncontrolled arterial hypertension (systolic pressure \> 170 mmHg or diastolic pressure \> 105 mmHg) 3. Severe renal dysfunction (serum creatinine \> 250 µmol/l) 4. Severe hepatic dysfunction (total bilirubin \> 40 µmol/l) 5. Known history of Human Immunodeficiency Virus or active Hepatitis B and C 6. Psychiatric or substance abuse disorders that would interfere with the cooperation with the requirements of the trial 7. Hypersensitivity to investigational drugs 8. Pregnant or breastfeeding females or males and females with childbearing potential must be willing to use an adequate method of birth control (intrauterine device, vasectomy of female subjects' male partner, contraceptive rod implanted into the skin, combination method - (requires use of two of the following) diaphragm with spermicide, cervical cap spermicide, contraceptive sponge, condom, hormonal contraceptive)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | From admission till discharge from the hospital (approximately 30 days) | The primary safety analysis will be based on subjects who experienced toxicities as defined by CTCAE criteria. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received BeEAC including serious adverse events (SAEs). Adverse experiences will be graded and recorded throughout the study and during the follow-up period according to NCI CTCAE 4.03. Toxicities will be characterized in terms regarding seriousness, causality, toxicity grading and action taking with regard to trial treatment (Incidence of Treatment-Emergent Adverse Events). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 2 years | — |
| Progression-Free Survival | 2 years | — |
| Retrospective Comparison of Overall Survival between Carmustine, Etoposide, Cytarabine, Melphalan (BEAM), Cyclophosphamide, Carmustine, Etoposide(CBV) and BeEAC conditioning regimens | 2 years | The analysis will be based on comparison of overall survival between different conditioning regimens |
| Retrospective Comparison of Progression-Free Survival between Carmustine, Etoposide, Cytarabine, Melphalan (BEAM), Cyclophosphamide, Carmustine, Etoposide(CBV) and BeEAC conditioning regimens | 2 years | The analysis will be based on comparison of Progression-Free survival between different conditioning regimens |
Countries
Russia
Contacts
Primary ContactVladislav Sarzhevskiy, MD, PhD
Backup ContactNikita Mochkin, MD, PhD
Outcome results
None listed